Peptide Pinning Schedule: Frequency, Timing, and Daily vs MWF Research Protocols

Peptide pinning frequency is determined by three factors: (1) the peptide's serum half-life, (2) the desired blood concentration profile, and (3) the receptor saturation or desensitization pattern for the target. General frequency rules: - Short half-life peptides (2-6 hours): often require 2-3 injections per day for steady-state concentrations - Medium half-life peptides (12-24 hours): daily injection typical - Medium-long half-life (36-72 hours): MWF (Monday/Wednesday/Friday) or EOD (every other day) schedules - Long half-life peptides (5-14 days): weekly injection Common research peptide schedules: - BPC-157: 250-500 mcg SQ, 1-2× daily (short half-life, continuous signaling) - TB-500: 2-5 mg SQ or IM, once weekly or loading + maintenance - CJC-1295 with DAC: 1-2 mg SQ, once weekly (DAC extends half-life dramatically) - CJC-1295 without DAC: 100 mcg SQ, 1-2× daily (short half-life) - Ipamorelin: 100-300 mcg SQ, 1-3× daily - Sermorelin: 100-500 mcg SQ, nightly at bedtime - Semaglutide (research): 0.25-2.4 mg SQ, once weekly - Tirzepatide (research): 2.5-15 mg SQ, once weekly - BPC-157 + TB-500 stack: BPC daily + TB weekly The schedule decision is biological, not arbitrary. Pinning BPC-157 once weekly would waste most of the dose (99%+ cleared from blood between doses). Pinning semaglutide daily would cause massive over-dosing and side effects. This content is for research and educational purposes only and does not constitute medical advice.

A peptide's half-life is the time required for its serum concentration to fall by 50%. After 4-5 half-lives, a peptide is essentially cleared from circulation. Peptides with 2-6 hour half-lives: - BPC-157 (research reports variable, 2-4 hours) - Sermorelin (~15-30 minutes — very short) - Ipamorelin (~2 hours) - GHRP-2, GHRP-6 (~20-30 minutes) These peptides produce pulsatile signaling — peak, rapid decline, then re-dose to create another peak. Multiple daily injections create multiple peaks resembling natural pulsatile hormonal release. For GHRH analogs (sermorelin, CJC-1295 without DAC), this pulsatile pattern may better preserve HPT-axis physiology than continuous signaling. Peptides with 12-24 hour half-lives: - BPC-157 pegylated variants - Some research GLP-1 modifications These suit daily dosing for steady blood concentrations. Peptides with 36-72 hour half-lives: - TB-500 (~2-3 days) - IGF-1 DES and LR3 (~1-2 days) These work well with every-other-day or MWF schedules. Peptides with 5-14+ day half-lives: - CJC-1295 with DAC (~5-8 days; DAC binds albumin and extends half-life dramatically) - Semaglutide (~5-7 days) - Tirzepatide (~5-6 days) - Ozempic formulations (similar to semaglutide) - Retatrutide (weekly) - Modified peptides with acetyl or PEG extensions These are once-weekly injections. Injecting more frequently would cause accumulation to supratherapeutic levels and side effects. Exceptions and nuances: - Some peptides have different half-lives in different tissues (e.g., BPC-157 may persist longer in target tissues than in serum) - Local vs systemic effects can decouple from serum half-life for injection-site-targeted peptides - Protein binding and metabolism vary between individuals, affecting effective half-life

Daily injection protocols suit peptides with half-lives of 6-24 hours where steady-state concentrations are desired. Common daily-dosed peptides: - BPC-157: 250-500 mcg SQ, once or twice daily - Ipamorelin: 100-300 mcg SQ, 1-3 times daily (often with CJC-1295 non-DAC) - Sermorelin: 100-500 mcg SQ at bedtime - Short-acting GHRPs: multiple times daily Daily protocol structure: Morning dosing: - Convenient routine integration - Maintains blood levels through the day - May align with natural cortisol peak for some metabolic effects - Consider: fasting state if sensitive to food intake Evening/bedtime dosing: - Preferred for GHRPs and GHRH analogs to align with natural sleep-related GH peak - Peak signaling during stage 3 sleep - May improve subjective sleep quality - Consider: separation from evening meal (30+ minutes) Split dosing (AM + PM): - Mimics natural pulsatile release better - Maintains more stable serum levels - Requires commitment to twice-daily injections - Increases injection site rotation complexity Practical considerations for daily protocols: - Fixed time of day improves compliance - Establish injection site rotation pattern (different site each day) - Keep supplies organized (pre-loaded syringes if safe, or supplies ready) - Document injection log for consistency - Inform travel plans (carry supplies safely, refrigeration for some peptides) Missed dose handling: - Single missed dose: usually minor impact; don't double up - Multiple missed doses: protocol restart may be needed depending on peptide - Cycle awareness: if you're 4 weeks into a 12-week cycle and miss a week, consider whether to extend cycle or accept shorter total duration Daily protocol sustainability: - Some users find daily injections manageable for months; others find them burdensome - Rotate injection sites rigorously to prevent scar tissue - Take breaks between cycles (4-week off periods common after 12-week cycles) - Monitor for injection-related complications (infection, nodule formation, lipohypertrophy)

Monday/Wednesday/Friday schedules suit peptides with 24-72 hour half-lives where 3× per week dosing produces consistent serum levels without daily injection burden. Common MWF-dosed peptides: - TB-500: 2-5 mg SQ on M/W/F (loading phase); then EOD or weekly maintenance - IGF-1 LR3: MWF or EOD dosing for short cycles - Some fertility protocols (HCG + HMG): MWF common MWF protocol structure: - Same day of week, same time when possible - Example: M/W/F at 8 AM after breakfast - Alternate injection sites on each pinning day - Weekend dose (Sunday or Saturday depending on protocol preference) vs no weekend (strict MWF) Benefits vs daily: - Lower injection burden (3× vs 7× per week) - Still maintains fairly steady serum levels for appropriate peptides - Reduces injection site scarring - Easier to schedule around work/life - Cost of materials halved compared to daily in some cases Benefits vs weekly: - More consistent serum levels than once-weekly for peptides with shorter half-lives - Better fits peptides with 36-72 hour half-lives (too long for daily, too short for weekly) - Allows gradual titration without weekly dose adjustments MWF timing considerations: - Uniform timing reduces variability - Morning vs evening depends on peptide and protocol goals - Consistency matters more than absolute timing MWF alternatives for similar half-life peptides: - EOD (every other day): similar concept but different day each week; some users prefer this for regularity - M/W/F is 'fixed schedule' (always same days) - EOD is 'relative schedule' (days shift each week) Practical tracking: - Keep a pinning calendar marking M/W/F - Note missed doses and consider adjusting schedule - Monitor for protocol effectiveness at expected timepoints - Some protocols describe 'loading phase' (more frequent) followed by 'maintenance phase' (less frequent) — MWF or weekly maintenance typical

Once-weekly injection protocols suit peptides with 5-14+ day half-lives. The long half-life comes from structural modifications (DAC linker, albumin binding, PEGylation) that extend the effective duration. Common weekly-dosed peptides: - CJC-1295 with DAC: 1-2 mg SQ weekly - Semaglutide (Wegovy/Ozempic formulations): 0.25-2.4 mg SQ weekly - Tirzepatide (Zepbound/Mounjaro): 2.5-15 mg SQ weekly - Retatrutide: 2-12 mg SQ weekly (trials ongoing) - Hand-full of specific long-acting research peptides Weekly protocol structure: - Same day of week at approximately same time (e.g., Sunday morning) - Large doses injected at one site - Rotate injection site between weeks - Steady-state concentration achieved after 4-6 weeks (5 half-lives) Benefits: - Minimal injection burden (1× per week) - Easy to remember - Compatible with patients who have injection aversion or schedule constraints - Insurance/pharmacy often stocks weekly dosing regimens easily Challenges: - Injection site reactions more common with larger bolus doses - Side effect timing correlates with injection (worst days 1-3 post-injection) - Missing a week has bigger impact than missing a day - Slower titration (each dose adjustment takes 2-4 weeks to see effect) Titration for weekly peptides (e.g., semaglutide): - Start low (0.25 mg weekly × 4 weeks) - Increase by small amounts every 4 weeks - Monitor for tolerability before each escalation - Maximum effect at therapeutic dose (typically 1.0-2.4 mg for semaglutide research) - Titration prevents severe GI side effects Storage considerations for weekly peptides: - Large vials typically used for multiple weeks of dosing - Refrigerate between use - Note expiration dates (most stable 28-42 days after reconstitution) - Protect from light exposure Combination protocols often involve: - Weekly semaglutide or tirzepatide for metabolic goals - Daily BPC-157 for recovery - Total injection burden: weekly + daily = 8 per week total - Requires organization but manageable with tracking app

Regardless of frequency, injection site rotation is critical to prevent: - Lipohypertrophy (fatty tissue deposits at repeated injection sites) - Scar tissue formation - Nerve damage at overused sites - Reduced absorption consistency - Skin discoloration - Local infection risk Common subcutaneous injection sites for peptides: 1. Abdomen (most common): - 2-3 inches from navel in all directions - Multiple sites available across belly area - Easy to see and access - Good absorption rate - Rotation pattern: work around clock-face position on abdomen 2. Upper outer thighs: - 4-6 inches below hip, 2-3 inches from outer side - Accessible but less convenient than abdomen - Slightly slower absorption - Good for some users 3. Upper outer arms: - Difficult to self-inject - Good for help from partner - Less commonly used for peptides 4. Buttocks (upper outer quadrant): - Larger muscle mass - Good for larger volume injections - Intramuscular option if needed - Less common for subcutaneous peptides Site rotation patterns: Daily dosing rotation: - Monday: abdomen, upper right - Tuesday: abdomen, upper left - Wednesday: thigh, right - Thursday: thigh, left - Friday: abdomen, lower right - Saturday: abdomen, lower left - Sunday: skip day, review MWF dosing rotation: - Monday: abdomen, upper right - Wednesday: abdomen, lower left - Friday: thigh, right - Next Monday: abdomen, upper left - Gradually cycle through all available sites Weekly dosing rotation: - Alternate abdomen quadrant each week - Quarterly, rotate to thigh for 4 weeks - Let sites rest fully (4+ weeks) before re-using Technique reminders: - Clean injection site with alcohol - Pinch skin fold (for SQ injections) - 45° or 90° angle (depending on technique and needle length) - Slow injection (2-5 seconds per mL) - Massage gently after (if protocol allows) - Dispose of needle in sharps container - Note injection site in log

Systematic tracking improves outcomes and safety: Daily tracking log: - Date and time of each injection - Peptide and dose - Injection site (map or notation) - Subjective response (1-10 scale for: energy, mood, sleep, pain, recovery, etc.) - Side effects noted Weekly summary: - Total injections completed - Protocol adherence (%) - Subjective trend (improving, stable, worsening) - Planned adjustments Monthly reports: - Protocol effectiveness review - Lab values (if applicable) - Cost analysis - Decision on continuing, adjusting, or discontinuing Photography (if relevant): - Progress photos monthly - Injection site documentation if concerns arise - Good documentation for specialist consultations Tools for tracking: - Dedicated protocol tracking app (like Dosed) - Spreadsheet with columns for date, time, peptide, dose, site, response - Physical journal with calendar - Voice memos logged to date What to do with the data: - Identify patterns (which dose levels correlate with best response?) - Correlate protocol with life events (work stress, sleep changes, exercise) - Share with healthcare provider if consulting - Decide when to adjust, continue, or cycle off - Protect future self (complete record if needed later) Typical cycling schedules: - 12 weeks on, 4 weeks off: common for GH-adjacent peptides - 8 weeks on, 4 weeks off: conservative approach - 16 weeks on, 8 weeks off: aggressive with longer rest - Continuous (with monitoring): some metabolic peptides like semaglutide This content is for research and educational purposes only and does not constitute medical advice. Peptide protocols carry medical, legal, and regulatory considerations — consult a licensed healthcare provider before starting any protocol.